Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare

Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CTXR)

Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo

PR Newswire August 13, 2020

Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

PR Newswire August 10, 2020

Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million

PR Newswire August 5, 2020

Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering

PR Newswire August 5, 2020

LD Micro - Announces Preliminary List of Presenters for the LD-500

Accesswire August 5, 2020

Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult

PR Newswire August 4, 2020

Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease Associated with COVID-19

PR Newswire July 22, 2020

Citius Pharmaceuticals to Present at the MoneyShow Accredited Investor Virtual Event

PR Newswire July 20, 2020

Citius Pharmaceuticals Brings on Myron S. Czuczman, M.D. as Chief Medical Officer (CMO) and Executive Vice President

PR Newswire July 14, 2020

Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

PR Newswire July 13, 2020

Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides

PR Newswire June 29, 2020

Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

GlobeNewswire June 29, 2020

Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with COVID-19

PR Newswire June 26, 2020

Virtual Conference for Life Sciences Companies Broadcast Live June 25, 2020

GlobeNewswire June 23, 2020

Citius Pharmaceuticals to Deliver Virtual Presentation at the Life Sciences Investor Forum

PR Newswire June 22, 2020

Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy

PR Newswire June 2, 2020

Citius Announces Expanded Access Program for Investigational Phase 3 Mino-Lok®

PR Newswire May 26, 2020

Citius Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire May 18, 2020

Citius Announces $7.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PR Newswire May 14, 2020

Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

PR Newswire May 13, 2020